Communication Issues in Patient and Provider Discussions of Immunotherapy
NCT05873608 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125
Last updated 2026-04-06
Summary
This trials studies communication issues in patient and provider discussions about immunotherapy. The goal of this study is to describe where patients have heard about immunotherapy, what the participants understand about it, how physicians and other healthcare workers describe immunotherapy, and how educational videos may support patient knowledge about immunotherapy.
Conditions
- Hematopoietic and Lymphoid System Neoplasm
- Malignant Solid Neoplasm
Interventions
- OTHER
-
Educational video
Testing an educational video
- OTHER
-
Interview
Participate in interview
- OTHER
-
Observation
Undergo observation
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Emory University
lead OTHER
Principal Investigators
-
Rebecca Pentz, PhD · Emory University Hospital/Winship Cancer Institute
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-06
- Primary Completion
- 2027-09-17
- Completion
- 2027-11-17
Countries
- United States
Study Locations
More Related Trials
-
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
NCT00048893 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00091338 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
NCT02556463 ·Status: TERMINATED ·Phase: PHASE1
-
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05896839 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT06324240 ·Status: RECRUITING ·Phase: PHASE1
-
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
NCT04847466 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT04616248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03546361 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03935893 ·Status: RECRUITING ·Phase: PHASE2
-
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
NCT00066651 ·Status: COMPLETED ·Phase: PHASE1
-
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
NCT00003022 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
NCT03030378 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
NCT00445965 ·Status: COMPLETED ·Phase: PHASE2
-
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
NCT03388632 ·Status: COMPLETED ·Phase: PHASE1
-
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
NCT00039091 ·Status: TERMINATED ·Phase: PHASE1
-
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
NCT03025256 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
NCT01026051 ·Status: TERMINATED ·Phase: PHASE2
-
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
NCT03175666 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
NCT02599454 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
NCT02298959 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03167177 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
NCT06218602 ·Status: RECRUITING ·Phase: PHASE2